Current Ratio
since 2005
Calculation
Bristol-Myers Squibb Co., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1.26 | = | 29,390) | ÷ | 23,417) |
| Dec 31, 2024 | 1.25 | = | 29,780) | ÷ | 23,774) |
| Dec 31, 2023 | 1.43 | = | 31,770) | ÷ | 22,262) |
| Dec 31, 2022 | 1.25 | = | 27,273) | ÷ | 21,890) |
| Dec 31, 2021 | 1.52 | = | 33,262) | ÷ | 21,868) |
| Dec 31, 2020 | 1.58 | = | 30,192) | ÷ | 19,080) |
| Dec 31, 2019 | 1.60 | = | 29,354) | ÷ | 18,304) |
| Dec 31, 2018 | 1.61 | = | 17,160) | ÷ | 10,654) |
| Dec 31, 2017 | 1.55 | = | 14,854) | ÷ | 9,563) |
| Dec 31, 2016 | 1.55 | = | 13,704) | ÷ | 8,841) |
| Dec 31, 2015 | 1.30 | = | 10,415) | ÷ | 8,017) |
| Dec 31, 2014 | 1.73 | = | 14,608) | ÷ | 8,461) |
| Dec 31, 2013 | 1.52 | = | 18,916) | ÷ | 12,440) |
| Dec 31, 2012 | 1.15 | = | 9,521) | ÷ | 8,279) |
| Dec 31, 2011 | 1.97 | = | 15,318) | ÷ | 7,780) |
| Dec 31, 2010 | 1.97 | = | 13,273) | ÷ | 6,739) |
| Dec 31, 2009 | 2.21 | = | 13,958) | ÷ | 6,313) |
| Dec 31, 2008 | 2.20 | = | 14,763) | ÷ | 6,710) |
| Dec 31, 2007 | 1.20 | = | 10,348) | ÷ | 8,644) |
| Dec 31, 2006 | 1.59 | = | 10,302) | ÷ | 6,496) |
| Dec 31, 2005 | 1.78 | = | 12,283) | ÷ | 6,890) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The current ratio for the period examined demonstrates fluctuations over time, generally remaining above 1.0, indicating a consistent ability to cover short-term liabilities with short-term assets. However, the ratio is not consistently stable and exhibits periods of both improvement and decline.
- Overall Trend
- From 2005 to 2025, the current ratio experienced considerable variability. Initial values were relatively strong, peaking in 2008 and 2009. A subsequent decline was observed through 2011, followed by another period of fluctuation before a more pronounced increase in 2019. The most recent years, 2020-2025, show a generally decreasing trend, though remaining above 1.0.
- Early Period (2005-2011)
- The current ratio began at 1.78 in 2005, decreasing to 1.59 in 2006. A more significant drop occurred in 2007, reaching 1.20. The ratio then improved substantially in 2008 and 2009, reaching 2.20 and 2.21 respectively. This was followed by a decline to 1.97 in 2010 and a stabilization at 1.97 in 2011. This period suggests a potential strengthening of short-term liquidity followed by a gradual normalization.
- Mid-Period (2012-2018)
- A notable decrease to 1.15 was observed in 2012, followed by a recovery to 1.52 in 2013 and 1.73 in 2014. The ratio then decreased slightly to 1.30 in 2015 before increasing again to 1.55 in both 2016 and 2017. A further increase to 1.61 was seen in 2018. This period indicates a moderate level of short-term liquidity with some volatility.
- Recent Period (2019-2025)
- The current ratio peaked at 1.60 in 2019, then decreased to 1.58 in 2020 and 1.52 in 2021. A more pronounced decline occurred in 2022, reaching 1.25, and continued to 1.25 in 2023. The ratio experienced a slight increase to 1.26 in 2025. This recent trend suggests a potential weakening in the company’s short-term liquidity position, although it remains above the benchmark of 1.0.
The fluctuations in the current ratio likely reflect changes in working capital management, short-term financing strategies, and overall business conditions. Further investigation into the underlying components of current assets and current liabilities would be necessary to determine the specific drivers of these trends.
AI Ask an analyst for more
Comparison to Competitors
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 1.26 | 0.67 | 1.14 | 1.87 | 1.58 | 1.55 | 1.03 | 1.54 | 1.16 | 4.13 | 1.89 | 2.90 |
| Dec 31, 2024 | 1.25 | 0.66 | 1.26 | 1.40 | 1.15 | 1.60 | 1.11 | 1.36 | 1.17 | 4.73 | 1.66 | 2.69 |
| Dec 31, 2023 | 1.43 | 0.87 | 1.65 | 1.68 | 0.94 | 1.43 | 1.16 | 1.25 | 0.91 | 5.69 | 1.75 | 3.99 |
| Dec 31, 2022 | 1.25 | 0.96 | 1.41 | 1.89 | 1.05 | 1.29 | 0.99 | 1.47 | 1.22 | 5.06 | 1.48 | 4.83 |
| Dec 31, 2021 | 1.52 | 0.79 | 1.59 | 1.43 | 1.23 | 1.27 | 1.35 | 1.27 | 1.40 | 3.56 | 1.50 | 4.46 |
| Dec 31, 2020 | 1.58 | 0.84 | 1.81 | 1.86 | 1.40 | 1.40 | 1.21 | 1.02 | 1.35 | 3.63 | 2.13 | 4.33 |
| Dec 31, 2019 | 1.60 | 3.18 | 1.44 | 5.19 | 1.16 | 3.10 | 1.26 | 1.24 | 0.88 | 3.67 | 1.92 | 3.61 |
| Dec 31, 2018 | 1.61 | 0.98 | 2.79 | 1.47 | 1.73 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 1.73 | 3.43 |
| Dec 31, 2017 | 1.55 | 1.28 | 5.49 | 1.43 | 1.32 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 1.34 | 3.28 |
| Dec 31, 2016 | 1.55 | 1.65 | 4.11 | 0.97 | 1.37 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 1.44 | 2.31 |
| Dec 31, 2015 | 1.30 | 1.50 | 4.44 | 1.27 | 1.53 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 1.38 | 2.78 |
| Dec 31, 2014 | 1.73 | 1.41 | 4.95 | 1.75 | 1.09 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 1.22 | 4.20 |
| Dec 31, 2013 | 1.52 | 2.59 | 3.44 | 2.01 | 1.47 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.16 | 3.99 |
| Dec 31, 2012 | 1.15 | 2.27 | 3.81 | 1.80 | 1.55 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 2.31 | 3.67 |
| Dec 31, 2011 | 1.97 | — | 4.80 | 1.50 | 1.60 | 5.53 | 2.38 | 2.04 | 2.06 | 4.40 | 1.55 | 3.39 |
| Dec 31, 2010 | 1.97 | — | 3.52 | 1.73 | 2.09 | 2.32 | 2.05 | 1.86 | 2.11 | 3.28 | 2.42 | 2.23 |
| Dec 31, 2009 | 2.21 | — | 4.89 | 1.89 | 1.90 | 2.57 | 1.82 | 1.80 | 1.66 | 4.55 | 2.76 | 4.59 |
| Dec 31, 2008 | 2.20 | — | 3.12 | 1.53 | 0.95 | 3.52 | 1.65 | 1.35 | 1.59 | 6.23 | 2.82 | 4.01 |
| Dec 31, 2007 | 1.20 | — | 2.11 | 1.40 | 2.33 | 4.11 | 1.51 | 1.23 | 2.15 | 2.81 | 1.93 | 2.49 |
| Dec 31, 2006 | 1.59 | — | 1.67 | 1.38 | 1.91 | 3.18 | 1.20 | 1.20 | 2.20 | 10.44 | 1.70 | 3.07 |
| Dec 31, 2005 | 1.78 | — | 2.57 | 1.30 | 1.89 | 6.79 | 2.48 | 1.58 | 1.47 | 8.46 | 1.71 | 3.84 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2025 | 1.26 | 1.30 |
| Dec 31, 2024 | 1.25 | 1.24 |
| Dec 31, 2023 | 1.43 | 1.27 |
| Dec 31, 2022 | 1.25 | 1.30 |
| Dec 31, 2021 | 1.52 | 1.36 |
| Dec 31, 2020 | 1.58 | 1.37 |
| Dec 31, 2019 | 1.60 | 1.66 |
| Dec 31, 2018 | 1.61 | 1.71 |
| Dec 31, 2017 | 1.55 | 1.74 |
| Dec 31, 2016 | 1.55 | 1.91 |
| Dec 31, 2015 | 1.30 | 1.90 |
| Dec 31, 2014 | 1.73 | 2.19 |
| Dec 31, 2013 | 1.52 | 2.17 |
| Dec 31, 2012 | 1.15 | 2.04 |
| Dec 31, 2011 | 1.97 | 2.30 |
| Dec 31, 2010 | 1.97 | 2.14 |
| Dec 31, 2009 | 2.21 | 1.95 |
| Dec 31, 2008 | 2.20 | 1.66 |
| Dec 31, 2007 | 1.20 | 1.74 |
| Dec 31, 2006 | 1.59 | 1.65 |
| Dec 31, 2005 | 1.78 | 1.82 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., current ratio, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2025 | 1.26 | 1.23 |
| Dec 31, 2024 | 1.25 | 1.21 |
| Dec 31, 2023 | 1.43 | 1.23 |
| Dec 31, 2022 | 1.25 | 1.23 |
| Dec 31, 2021 | 1.52 | 1.31 |
| Dec 31, 2020 | 1.58 | 1.30 |
| Dec 31, 2019 | 1.60 | 1.48 |
| Dec 31, 2018 | 1.61 | 1.52 |
| Dec 31, 2017 | 1.55 | 1.55 |
| Dec 31, 2016 | 1.55 | 1.73 |
| Dec 31, 2015 | 1.30 | 1.70 |
| Dec 31, 2014 | 1.73 | 1.92 |
| Dec 31, 2013 | 1.52 | 1.96 |
| Dec 31, 2012 | 1.15 | 1.84 |
| Dec 31, 2011 | 1.97 | 1.94 |
| Dec 31, 2010 | 1.97 | 1.81 |
| Dec 31, 2009 | 2.21 | 1.78 |
| Dec 31, 2008 | 2.20 | 1.44 |
| Dec 31, 2007 | 1.20 | 1.53 |
| Dec 31, 2006 | 1.59 | 1.39 |
| Dec 31, 2005 | 1.78 | 1.63 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).